Komal Exporters Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Komal Exporters Pharmaceutical Export Portfolio Dataset — 3 Products, $90.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Komal Exporters — Pharmaceutical Exporter Profile (2026) | 3 Products, $90.6K Trade | TransData Nexus

Product Portfolio — Top 3 by Export Value

Komal Exporters exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Volini	Brand Names & OTC Products	$43.1K	65	1.5%	4
2	Betadine	Brand Names & OTC Products	$42.3K	85	0.6%	8
3	Neosporin	Brand Names & OTC Products	$5.2K	34	5.2%	7

Komal Exporters exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $90.6K. The top category is Brand Names & OTC Products (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Komal Exporters — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

Komal Exporters, established in 1998, is a privately held Indian company specializing in the export of pharmaceutical products. The company is registered under the Goods and Services Tax Network (GSTN) with the registration number 33AAGPA7113G1ZC. Its headquarters are located at 17/4, Chitrakulam West Street, Pushkarni, Chennai, Tamil Nadu, 600004, India. The company operates as a sole proprietorship, with an active status as of January 5, 2026. Specific details regarding revenue, employee count, and the website are not publicly disclosed.

2Manufacturing Facilities

Komal Exporters does not own or operate any manufacturing facilities. The company focuses on the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, sourced from third-party manufacturers. This strategy allows Komal Exporters to offer a diverse product portfolio without the capital investment required for manufacturing operations.

3Key Leadership

Information regarding the key leadership of Komal Exporters, including the CEO, CFO, and other executives, is not publicly available. The company's sole proprietorship structure suggests that it is managed by a single individual, but specific details are not disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Komal Exporters Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Komal Exporters has a limited presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan. The company's export activities primarily focus on over-the-counter (OTC) pharmaceutical products, which may not require extensive regulatory approvals in these regions. However, the lack of publicly available information on specific regulatory filings and approvals indicates that Komal Exporters may not have significant market access in these countries.

2Emerging Markets

Komal Exporters has demonstrated a presence in emerging markets, particularly in Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to various countries in these regions, suggesting an active engagement in these markets. While specific details on WHO prequalification are not available, the company's focus on OTC products may facilitate easier market entry in these regions.

3Geographic Strategy

Komal Exporters' geographic strategy appears to be focused on exporting OTC pharmaceutical products to a diverse range of countries, including both regulated and emerging markets. The company's export data indicates shipments to various countries, suggesting a broad market reach. However, the lack of significant market share in any specific region indicates a relatively low concentration risk. The company's strategic direction seems to be centered on leveraging its product portfolio to cater to a wide array of markets.

Komal Exporters — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

There is no publicly available information indicating that Komal Exporters has FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or a history of FDA inspections. This suggests that the company may not be actively engaged in exporting pharmaceutical products to the United States or may not have pursued FDA approvals for its products.

2WHO & EU GMP

Specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status for Komal Exporters are not publicly available. The company's focus on OTC products may reduce the necessity for such certifications, but the lack of publicly available information indicates that these certifications may not be in place.

3CDSCO & Indian Regulatory

Komal Exporters is registered with the Central Drugs Standard Control Organisation (CDSCO) under the Goods and Services Tax Network (GSTN) with the registration number 33AAGPA7113G1ZC. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly available. The company's focus on exporting finished pharmaceutical formulations suggests compliance with Indian regulatory requirements, but detailed information is not disclosed.

Komal Exporters — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Komal Exporters operates in a competitive landscape with numerous pharmaceutical exporters in India. While specific competitors are not identified, the company's focus on OTC pharmaceutical products positions it in competition with other exporters offering similar product portfolios. The lack of significant market share in any specific region indicates that Komal Exporters holds a modest position in the global market.

2Key Differentiators

Komal Exporters' key differentiators include its specialization in exporting finished pharmaceutical formulations, particularly OTC products, and its ability to source a diverse range of products from third-party manufacturers. This strategy allows the company to offer a broad product portfolio without the capital investment required for manufacturing operations. However, the lack of significant market share in any specific region suggests that the company may face challenges in differentiating itself from competitors.

3Strategic Position

Komal Exporters' current strategic direction appears to be centered on exporting OTC pharmaceutical products to a diverse range of markets, including both regulated and emerging regions. The company's focus on finished formulations allows it to cater to a wide array of customer needs. However, the lack of significant market share in any specific region indicates that the company may need to enhance its competitive positioning to achieve greater market penetration.

Buyer Due Diligence Brief — Evaluating Komal Exporters as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Komal Exporters' track record in exporting pharmaceutical products is characterized by a total export value of $91,000 USD across 184 shipments, with a portfolio concentration where the top three products—Volini, Betadine, and Neosporin—account for 100% of the export value. This indicates a high reliance on a limited product range, which may pose risks related to market demand fluctuations. The company's export data suggests a consistent volume of shipments, but the lack of significant market share in any specific region indicates potential challenges in achieving broader market acceptance.

2Certifications to Verify

Importers should verify the following certifications when considering products from Komal Exporters:

FDA Approval: Confirm that the product is listed in the FDA's Orange Book or has an approved ANDA. Verification can be done through the FDA's official website.

WHO-GMP Certification: Ensure that the manufacturing facility holds a valid WHO-GMP certificate. This can be verified through the World Health Organization's official website.

Frequently Asked Questions — Komal Exporters

How many pharmaceutical products does Komal Exporters export from India?

Komal Exporters exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Volini ($43.1K), Betadine ($42.3K), Neosporin ($5.2K). Total export value is $90.6K.

What is Komal Exporters's total pharmaceutical export value?

Komal Exporters's total pharmaceutical export value is $90.6K, based on 184 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Komal Exporters cover?

Komal Exporters exports across 1 therapeutic categories. The largest are Brand Names & OTC Products (100.0%, 3 products).

Get Full Komal Exporters Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.

Komal Exporters

Komal Exporters — Export Portfolio & Destination Treemap

Who is Komal Exporters? — Company Overview & Market Position

What Does Komal Exporters Export? — Product Portfolio Analysis

Top Products by Export Value

Komal Exporters Therapeutic Categories — 1 Specializations